Evidence map›Paper›PMID 26826706›Full record

ArticleHistopathology2016

Distribution of the c-MYC gene product in colorectal neoplasia.

Ann-Marie Baker, Susan Van Noorden, Manuel Rodriguez-Justo, Patrizia Cohen, Nicholas A Wright, Irvin A Lampert

Open access · hybridAbstract read
In one paragraph

Article in Histopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Unraveling the Effects and Characteristics of Proliferating Tumor and Cytotoxic T Cells in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2021
    Article
  3. ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Ann-Marie BakerCentre for Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Susan Van NoordenDepartment of Histopathology, Imperial College London, Hammersmith Hospital, London, UK.
Manuel Rodriguez-JustoDepartment of Histopathology, University College London, London, UK.
Patrizia CohenDepartment of Cellular Pathology, Clarence Memorial Wing, St Mary's Hospital, London, UK.
Nicholas A WrightCentre for Tumour Biology, Barts Cancer Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Irvin A LampertDepartment of Histopathology, West Middlesex University Hospital, Isleworth, UK.
Queen Mary University of London · GBHammersmith Hospital · GBSt Mary's Hospital · CAUniversity College London · GBWest Middlesex University Hospital · GB

Funding

Cancer Research UK 14895
6 · The paper itself

Abstract

aimsRecent attempts to study MYC distribution in human samples have been confounded by a lack of agreement in immunohistochemical staining between antibodies targeting the N-terminus and those targeting the C-terminus of the MYC protein. The aim of this study was to use a novel in-situ hybridization (ISH) approach to detect MYC mRNA in clinically relevant samples, and thereby determine the reliability of MYC-targeting antibodies. METHODS AND

resultsWe performed immunohistochemistry on human formalin-fixed paraffin embedded normal colon (n = 15), hyperplastic polyp (n = 4) and neoplastic colon samples (n = 55), using the N-terminally directed antibody Y69, and the C-terminally directed antibody 9E10. The MYC protein distributions were then compared with the location of MYC mRNA, determined by ISH. We found that the localization of MYC mRNA correlated well with the protein distribution determined with the N-terminally directed antibody Y69, and was also associated with expression of the proliferation marker Ki67. The protein distribution determined with the C-terminally directed antibody 9E10 was not always associated with MYC mRNA, Y69, or Ki67, and indeed often showed a reciprocal pattern of expression, with staining being strongest in non-proliferating cells.

conclusionsThe observed discrepancy between the staining patterns suggests that the significance of 9E10 in immunohistochemical staining is currently uncertain, and therefore should be interpreted with caution.

Indexed as

AdenocarcinomaAdenomaAntibodies, MonoclonalColonColonic NeoplasmsColonic PolypsColorectal NeoplasmsHumansImmunohistochemistryIn Situ HybridizationProto-Oncogene Proteins c-mycReproducibility of ResultsRNA, MessengerAntibodies, MonoclonalMYC protein, humanProto-Oncogene Proteins c-mycRNA, Messengerc-MYCcolorectal cancerimmunohistochemistryin-situ hybridization

Identifiers

PMID26826706
PMCPMC4949543
OpenAlexW2299218195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.